GLPGN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base give durable financial flexibility for a capital‑intensive biotech. This reduces insolvency and refinancing risk, allowing multi‑period funding of R&D and clinical programs without immediate reliance on markets or partners.
High And Sustainable MarginsVery high gross and operating margins indicate strong pricing power or favorable revenue mix, which supports long‑term profitability even if top‑line fluctuates. Durable margins improve cash retention potential and the ability to fund strategic programs once cash flow turns.
Improving Returns On CapitalROE improvement to ~16% shows management is generating stronger returns from its equity base. Combined with the large equity cushion, this creates a durable capacity to invest in growth initiatives and absorb near‑term losses without immediate capital raises.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business is not self‑funding and must draw on equity or financing to continue operations. Over months this raises dilution or financing risk and constrains the firm's ability to scale without tapping its balance sheet.
Revenue Volatility And Recent DeclineTop‑line instability—declining revenue following a prior step‑up—reduces predictability for R&D spend and operating planning. Over a 2–6 month horizon, uneven revenue trends complicate resource allocation and increase the chance that margins or investment plans will be adjusted.
Historic Earnings VolatilityA track record of earnings swings implies current profitability may be unstable. For a biotech, binary outcomes and uneven commercial uptake can reverse earnings quickly, making current margin and ROE improvements less certain as durable indicators of future performance.
GLPGN FAQ
What was Galapagos NV (UK)’s price range in the past 12 months?
Currently, no data Available
What is Galapagos NV (UK)’s market cap?
Galapagos NV (UK)’s market cap is $31.78B.
When is Galapagos NV (UK)’s upcoming earnings report date?
Galapagos NV (UK)’s upcoming earnings report date is Aug 10, 2026 which is in 8 days.
How were Galapagos NV (UK)’s earnings last quarter?
Galapagos NV (UK) released its earnings results on May 06, 2026. The company reported $4.203 earnings per share for the quarter, beating the consensus estimate of -$16.311 by $20.514.
Is Galapagos NV (UK) overvalued?
According to Wall Street analysts Galapagos NV (UK)’s price is currently Undervalued.
Does Galapagos NV (UK) pay dividends?
Galapagos NV (UK) does not currently pay dividends.
What is Galapagos NV (UK)’s EPS estimate?
Galapagos NV (UK)’s EPS estimate is -14.01.
How many shares outstanding does Galapagos NV (UK) have?
Galapagos NV (UK) has 65,897,070 shares outstanding.
What happened to Galapagos NV (UK)’s price movement after its last earnings report?
Galapagos NV (UK) reported an EPS of $4.203 in its last earnings report, beating expectations of -$16.311. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Galapagos NV (UK)?
Currently, no hedge funds are holding shares in MX:GLPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos NV (UK)
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
GLPGN Stock 12 Month Forecast
Average Price Target
$452.50